Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.68 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338558 | 0.89 | GABRA1 (0.75) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL3847939 | 0.86 | GABRA1 (0.73) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL25201098 | 0.85 | GABRA1 (0.71) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL25195018 | 0.85 | GABRA1 (0.61) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL25193812 | 0.85 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL28289134 | 0.84 | GABRA1 (0.70) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL22589629 | 0.84 | KDM4E (0.62) | MEN1ALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL29366524 | 0.84 | KDM4E (0.62) | MEN1ALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL846416 | 0.83 | GABRA1 (0.74) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL25184813 | 0.82 | GABRA1 (0.55) | GABRA1GABRB2GABRB1GABRA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| CN-119798159-A | PAPD5 inhibitors and methods of use thereof | 儿童医学中心公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20220274928-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-09-01 | — | — | US | disclosed |
| EP-3959197-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-113993848-A | Inhibitors of PAPD5 and methods of use thereof | 儿童医学中心公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020219729-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219729-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274928-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | GABRA1 4735/4885GABRB2 4741/4885GABRB1 4730/4885 |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | GABRA1 1758/4885GABRB2 1514/4885GABRB1 1187/4885 |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | GABRA1 4735/4885GABRB2 4741/4885GABRB1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.